08
Feb
2012
08
Feb
2012
08
Feb
2012
07
Feb
2012
07
Feb
2012
06
Feb
2012
03
Feb
2012
03
Feb
2012
31
Jan
2012
31
Jan
2012
30
Jan
2012
Posted in I - Series B, Q - 4Q11, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Inflammation, X - Oncology, X - Therapeutic Platform
arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.
26
Jan
2012
26
Jan
2012